Moderna (NASDAQ:MRNA) President Stephen Hoge Sells 40,294 Shares of Stock

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 40,294 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $144.13, for a total transaction of $5,807,574.22. Following the completion of the transaction, the president directly owned 1,525,858 shares of the company’s stock, valued at $219,921,913.54. This represents a 2.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Stephen Hoge also recently made the following trade(s):

• On Tuesday, September 15th, Stephen Hoge sold 40,281 shares of Moderna stock. The shares were sold at an average price of $146.07, for a total transaction of $5,883,845.67.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $145.62 on Thursday. The company’s fifty day moving average is $96.37 and its two-hundred day moving average is $68.84. The company has a market cap of $58.14 billion, a P/E ratio of -18.23 and a beta of 1.10. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $176.66. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09.

Moderna (NASDAQ:MRNA) last issued its earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping the consensus estimate of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The business had revenue of $145.00 million during the quarter, compared to analysts’ expectations of $102.93 million. During the same quarter last year, the firm posted ($2.13) earnings per share. Moderna’s revenue was up 2.1% compared to the same quarter last year. Equities analysts expect that Moderna, Inc. will post -6.09 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently commented on MRNA shares. Citigroup boosted their price objective on shares of Moderna from $41.00 to $60.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. The Goldman Sachs Group lifted their target price on shares of Moderna from $67.00 to $120.00 and gave the company a “neutral” rating in a research note on Wednesday, August 19th. Bradesco Corretora raised shares of Moderna to an “outperform” rating in a research note on Friday, August 28th. JPMorgan Chase & Co. increased their price objective on Moderna from $40.00 to $77.00 and gave the stock an “underweight” rating in a report on Friday, August 21st. Finally, Jefferies Financial Group reissued a “hold” rating on shares of Moderna in a research report on Wednesday, August 19th. Seven investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and five have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $76.72.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new position in Moderna in the 2nd quarter worth $2,142,877,000. Theleme Partners LLP bought a new stake in Moderna in the 2nd quarter valued at $564,272,000. Capital World Investors acquired a new position in shares of Moderna in the 4th quarter valued at $378,299,000. Wellington Management Group LLP lifted its holdings in shares of Moderna by 4.4% during the 2nd quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock worth $172,384,000 after acquiring an additional 103,977 shares during the period. Finally, Merck & Co. Inc. acquired a new stake in shares of Moderna during the 2nd quarter valued at about $161,642,545. 75.33% of the stock is owned by institutional investors.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Investor optimism is building around Moderna’s personalized cancer-vaccine program and its collaboration with Merck. Analysts see oncology as a potential long-term growth engine that could help offset weaker COVID-19 vaccine revenue and support a broader business turnaround. Speculation that Merck could acquire Moderna adds to the strategic appeal, although no transaction has been announced. Why Merck Should Buy Moderna
• Positive Sentiment: Recent coverage highlights Moderna’s strong stock recovery and investors’ growing willingness to value the company on its pipeline rather than solely on COVID-19 products. Moderna’s latest quarterly revenue also exceeded expectations, providing some support for the recovery narrative. Is Cancer the Turnaround Moderna Has Been Looking for Post-COVID?
• Neutral Sentiment: Institutional ownership remains substantial, with major investors including BlackRock and California State Teachers’ Retirement System reporting sizable positions. This may improve trading support, but the cited holdings largely reflect earlier reporting periods rather than a new catalyst.
• Neutral Sentiment: Analyst opinion remains mixed: Moderna has Buy, Hold and Sell ratings, with a consensus Hold rating. This suggests investors recognize the pipeline opportunity but remain cautious about valuation, execution and the company’s path back to profitability.
• Negative Sentiment: President Stephen Hoge sold a combined 80,575 shares worth approximately $11.7 million over September 14–15. CFO James Mock also sold 34,836 shares, reducing his direct holdings by about 37%. All reported transactions were made under pre-arranged Rule 10b5-1 plans, limiting their value as discretionary bearish signals, but the insider selling could still weigh on sentiment. Moderna SEC insider-trading filing

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops messenger RNA (mRNA) medicines and vaccines. Its platform is designed to provide cells with instructions to produce proteins that may help prevent or treat infectious diseases, cancer and other medical conditions.

The company’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. Moderna also maintains a pipeline of investigational programs in areas such as seasonal influenza, cytomegalovirus, oncology and rare diseases.

Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna serves markets in the United States and internationally through regulatory approvals, commercial partnerships and distribution arrangements.